Whalesbook
So, NSO ki latest report ne toh hosh uda diye hain. Piche 7 saal mein cardiovascular diseases (CVDs) yaani dil ki bimariyon ke cases lagbhag 3x ho gaye hain. Ab toh ye desh ki sabse badi health problem ban gayi hai, almost 25.6% cases isi ke hain.
Aur shocking baat ye hai ki ye 15 se 29 saal ke young logon mein bhi 2.1% aa gaya hai. Iski wajah se healthcare system pe overload aur logon ki jeb par bojh bahut zyada ho gaya hai. Shehron mein ek baar treatment ka kharcha lagbhag ₹69,451 aa raha hai.
Par is sab crisis ke beech ek interesting baat hai - India ka healthcare sector rukka nahi, balki joron shoron se boom kar raha hai! Nifty Healthcare Index toh pichle 1 saal mein hi 46% bhaga hai, market se bhi zyada. Experts keh rahe hain ki Indian healthcare market saal mein 18-20% CAGR se badhega.
Healthtech aur pharma mein toh kamaal ho raha hai. Pharma business 2030 tak $130 billion tak pahunch jayega aur hospital sector 2032 tak $193.6 billion ka ho jayega. Achhi baat ye hai ki health insurance coverage bhi 3 guna ho gaya hai, aur gaon mein toh sheheron se zyada penetration hai.
Is boom ka fayda pharma companies ko mil raha hai, jaise Sun Pharma, Cipla, Dr. Reddy's, kyunki chronic diseases ke liye medicine ki demand bani hui hai. Diagnostic centers jaise Dr. Lal PathLabs aur Metropolis Healthcare bhi chamak rahe hain. Hospitals jaise Apollo, Fortis, Max bhi apni capacity badha rahe hain. Ye sector toh COVID mein bhi sabse pehle recover hua tha, matlab economic downfall mein bhi stable rehta hai.
Lekin bhai, sab kuch perfect nahi hai. Itna sab hone ke baad bhi, log abhi bhi paison ke liye struggle kar rahe hain. Jab log hospital mein admit hote hain, tab bhi 95% tak (gaon mein) aur 83% tak (sheheron mein) unhe apni jeb se kharcha karna padta hai, insurance hone ke baad bhi. Medical tech aur staff ka kharcha bhi badh raha hai. Government ka healthcare par kharcha bhi targets se kam hai.
Aage dekha jaaye toh digitalization, healthtech, aur telemedicine sector ko aur bhi boost dega. Hospital chains se revenue growth ki ummeed hai. Ab focus preventive care par ja raha hai, par sabse important hai ki mahange treatment ko sabke liye affordable banana. Jo companies regulations samajhti hain aur NCD management mein acchi hain, unme paisa lagne ki ummeed hai.